As a lead author on a recent study published in the Lancet, Prof Chris Twelves discusses how treatment with eribulin extends lives of heavily pre-treated breast cancer patients compared with treatments of physician’s choice (EMBRACE study).

Extending the lives of women who have had extensive treatment for breast cancer that has spread is not a lost cause, conclude authors of a study published Online First in The Lancet. The study shows that monotherapy with the drug eribulin extends the lives of breast cancer patients by a median 2.5 months compared with the treatment of the physician’s choice (median survival 13.1 vs 10.6 months). Eribulin, brand name Halaven, is a new chemotherapy drug that binds microtubules - structures that form the scaffolding that allows cell division - in a different way to existing chemotherapy drugs.

Cortes J et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet 2011.



This programme was made possible with sponsorship from Eisai Europe Ltd.